Scarica l'app Stockscreener
1.21
0.82%
-0.01
Pre-mercato:
1.21
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
EBIT per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Hedge Fund Bets: Will Silexion Therapeutics Corp Equity Warrant benefit from government policy2026 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Market Recap: Whats the profit margin of Silexion Therapeutics Corp2026 Historical Comparison & Technical Entry and Exit Alerts - baoquankhu1.vn
Shorts Report: Whats the beta of Silexion Therapeutics Corp Equity Warrant stock2026 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Top Silexion Executive Quietly Unloads a Chunk of Company Stock - TipRanks
Silexion Therapeutics (SLXN) CSO logs sale-to-cover share transaction - stocktitan.net
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - MSN
Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Trial of SIL204 in Locally Advanced Pancreatic Cancer - geneonline.com
Investor Mood: Can Silexion Therapeutics Corp be recession proofWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Silexion Therapeutics Announces Immediate Board Membership Change - tipranks.com
Ilan Levin removed from Silexion Therapeutics board - TradingView
Board at Silexion Therapeutics (NASDAQ: SLXN) removes Ilan Levin - Stock Titan
Is Silexion Therapeutics Corp a strong growth stockMarket Weekly Review & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204 - TipRanks
Silexion Shareholders Reject Capital Increase and Plan Amendments - The Globe and Mail
Silexion Therapeutics Receives Israeli Ministry of Health Approval for Phase 2/3 Clinical Trial of SIL204 in Advanced Pancreatic Cancer - minichart.com.sg
Silexion gets Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire
Silexion gains approval for SIL204 pancreatic cancer trial - TipRanks
Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment - Benzinga
Regulators clear Silexion (NASDAQ: SLXN) to begin SIL204 pancreatic cancer trial - Stock Titan
Silexion receives Israeli approval for pancreatic cancer trial - Investing.com
Silexion Therapeutics Corp Receives Approval to Initiate Phase 2/3 Clinical Trial Of SIL204 in Locally Advanced Pancreatic Cancer - MarketScreener
Silexion Therapeutics Corp 8-K Filing – Share Capital Increase Proposal Not Approved (March 2026) - Minichart
Silexion Therapeutics Corp announced plans to submit its Phase 2/3 clinical trial application to German regulators by the end of this quarter. - bitget.com
Silexion Therapeutics shareholders reject share capital and equity plan increases By Investing.com - Investing.com South Africa
Silexion Therapeutics shareholders reject share capital and equity plan increases - Investing.com India
Shareholders at Silexion (SLXN) vote down capital and evergreen increase proposals - Stock Titan
Growth Report: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soon2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn
EPS Watch: Can Silexion Therapeutics Corp Equity Warrant expand its profit margins2026 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Form 8K Silexion Therapeutics Corp For: 3 February - Investing.com
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Maintains Target Price $6 - 富途牛牛
Tangible book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
SLXNW Financials: Income Statement, Balance Sheet & Cash Flow | Silexion Therapeutics Corp - Stock Titan
Silexion Therapeutics Corp: Clinical-Stage KRAS Oncology Innovations and siRNA Pipeline for Pancreatic Cancer - Minichart
Silexion Therapeutics Reports 2025 Financial Results and Clinical Program Updates - geneonline.com
Biotech Silexion lines up 2026 pancreatic cancer trial after $18.6M cash raise - Stock Titan
Silexion Therapeutics 10-K: $11.9M net loss, cash $6.08M; operating loss $11.63M - TradingView
Silexion Therapeutics (NASDAQ: SLXN) outlines SIL204 KRAS cancer strategy in 10-K - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Growth Recap: Is Silexion Therapeutics Corp Equity Warrant a potential multi baggerTrade Volume Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
Setup Watch: Can Silexion Therapeutics Corp Equity Warrant stock outperform in a bear marketBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Silexion Therapeutics Corp Auditor Raises 'Going Concern' Doubt - MarketScreener
SLXN SEC FilingsSilexion Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM) - The Globe and Mail
Fed Meeting: Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soonQuarterly Profit Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting - Bitget
Rally Mode: Is Silexion Therapeutics Corp a defensive stock2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
SLXN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
EPS Watch: Is First Light Acquisition Group Inc Equity Warrant vulnerable to short sellersQuarterly Portfolio Report & Smart Allocation Stock Tips - baoquankhu1.vn
SLXN Should I Buy - Intellectia AI
EBITDA per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Market Fear: Should value investors consider CompoSecure Inc Equity WarrantMarket Activity Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Equity grants to director-linked fund at Silexion Therapeutics (SLXN) disclosed - Stock Titan
Director Alon Ruth receives Silexion (SLXN) share and stock option grants - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):